Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 32Active not recruiting 23Completed 5Terminated 2Suspended 2Not yet recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1HTLV-I Infections 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Specimen Handling 21Biopsy 14Magnetic Resonance Spectroscopy 13Cyclophosphamide 4Nivolumab 3Cetuximab 3Azacitidine 3venetoclax 2trastuzumab deruxtecan 2decitabine and cedazuridine drug combination 2X-Rays 2Vincristine 2Taxes 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Prednisone 2Practice Guidelines as Topic 2Lenalidomide 2Ipilimumab 2Etoposide 2Doxorubicin 2CTLA-4 Antigen 2(225)Ac-DOTA-c(RGDyK) 2spartalizumab 1relatlimab 1prednylidene 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Prednisone × 30 days × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04803201 2026-05-06

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡